Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies

Abstract Introduction Patients with benign or malignant blood disorders, who require allogeneic stem cell transplantation and lack an identical human leukocyte antigen HLA identicalHL sibling donor, could be transplanted with hematopoietic stem cells from unrelated adult or umbilical cord donors. However, in our country, both approaches are costly and time-consuming options. Methods Over the last few years, haploidentical modalities have been investigated as an alternative donor source, showing similar results to those obtained with identical HLA donors. We started using T-cell-replete haploidentical with post-transplant cyclophosphamide in 2012 and we presented our experience with patients undergoing haploidentical ransplantation compared to SIB. Results Since January 2012 to date, 91 allogeneic transplants have been performed, of which 49 were haploidentical and 42 were HLA identical. The mean age of the patients was 35 years (range: 17–62). The mean CD34/kg × 106 infused per group was 5.93 and 5.89, respectively. Time to granulocyte and platelet engraftment was 11 and 15 days, respectively, for haploidentical, and 12 and 14 days, respectively, for HLA identical (p = 0.10). The 100-day cumulative incidence of global acute GVHD was 34% for haploidentical and 29% for SIHLA identical (p = 0.9). The 2-year overall global graft-versus-host disease was 43% for haploidentical and 41% for HLA identical (p = 0.8). Overall survival, relapse, and transplant and relapse-related mortality were similar between both groups. Conclusion Our experience showed that haploidentical has similar outcomes to those obtained with HLA idential and can be performed in our country safely.

Saved in:
Bibliographic Details
Main Authors: Sarmiento,Mauricio, Ramirez,Pablo, Jara,Veronica, Bertin,Pablo, Galleguillos,Mauricio, Rodriguez,Isabel, Lorca,Carla, Pizarro,Isabel, Rivera,Elizabeth, Ocqueteau,Mauricio
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000100040
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2531-13792020000100040
record_format ojs
spelling oai:scielo:S2531-137920200001000402020-03-25Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathiesSarmiento,MauricioRamirez,PabloJara,VeronicaBertin,PabloGalleguillos,MauricioRodriguez,IsabelLorca,CarlaPizarro,IsabelRivera,ElizabethOcqueteau,Mauricio Leukemia Lymphoma Haploidentical transplantation Abstract Introduction Patients with benign or malignant blood disorders, who require allogeneic stem cell transplantation and lack an identical human leukocyte antigen HLA identicalHL sibling donor, could be transplanted with hematopoietic stem cells from unrelated adult or umbilical cord donors. However, in our country, both approaches are costly and time-consuming options. Methods Over the last few years, haploidentical modalities have been investigated as an alternative donor source, showing similar results to those obtained with identical HLA donors. We started using T-cell-replete haploidentical with post-transplant cyclophosphamide in 2012 and we presented our experience with patients undergoing haploidentical ransplantation compared to SIB. Results Since January 2012 to date, 91 allogeneic transplants have been performed, of which 49 were haploidentical and 42 were HLA identical. The mean age of the patients was 35 years (range: 17–62). The mean CD34/kg × 106 infused per group was 5.93 and 5.89, respectively. Time to granulocyte and platelet engraftment was 11 and 15 days, respectively, for haploidentical, and 12 and 14 days, respectively, for HLA identical (p = 0.10). The 100-day cumulative incidence of global acute GVHD was 34% for haploidentical and 29% for SIHLA identical (p = 0.9). The 2-year overall global graft-versus-host disease was 43% for haploidentical and 41% for HLA identical (p = 0.8). Overall survival, relapse, and transplant and relapse-related mortality were similar between both groups. Conclusion Our experience showed that haploidentical has similar outcomes to those obtained with HLA idential and can be performed in our country safely.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.42 n.1 20202020-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000100040en10.1016/j.htct.2019.01.010
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Sarmiento,Mauricio
Ramirez,Pablo
Jara,Veronica
Bertin,Pablo
Galleguillos,Mauricio
Rodriguez,Isabel
Lorca,Carla
Pizarro,Isabel
Rivera,Elizabeth
Ocqueteau,Mauricio
spellingShingle Sarmiento,Mauricio
Ramirez,Pablo
Jara,Veronica
Bertin,Pablo
Galleguillos,Mauricio
Rodriguez,Isabel
Lorca,Carla
Pizarro,Isabel
Rivera,Elizabeth
Ocqueteau,Mauricio
Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
author_facet Sarmiento,Mauricio
Ramirez,Pablo
Jara,Veronica
Bertin,Pablo
Galleguillos,Mauricio
Rodriguez,Isabel
Lorca,Carla
Pizarro,Isabel
Rivera,Elizabeth
Ocqueteau,Mauricio
author_sort Sarmiento,Mauricio
title Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
title_short Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
title_full Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
title_fullStr Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
title_full_unstemmed Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies
title_sort haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in chilean patients with benign and malignant hemopathies
description Abstract Introduction Patients with benign or malignant blood disorders, who require allogeneic stem cell transplantation and lack an identical human leukocyte antigen HLA identicalHL sibling donor, could be transplanted with hematopoietic stem cells from unrelated adult or umbilical cord donors. However, in our country, both approaches are costly and time-consuming options. Methods Over the last few years, haploidentical modalities have been investigated as an alternative donor source, showing similar results to those obtained with identical HLA donors. We started using T-cell-replete haploidentical with post-transplant cyclophosphamide in 2012 and we presented our experience with patients undergoing haploidentical ransplantation compared to SIB. Results Since January 2012 to date, 91 allogeneic transplants have been performed, of which 49 were haploidentical and 42 were HLA identical. The mean age of the patients was 35 years (range: 17–62). The mean CD34/kg × 106 infused per group was 5.93 and 5.89, respectively. Time to granulocyte and platelet engraftment was 11 and 15 days, respectively, for haploidentical, and 12 and 14 days, respectively, for HLA identical (p = 0.10). The 100-day cumulative incidence of global acute GVHD was 34% for haploidentical and 29% for SIHLA identical (p = 0.9). The 2-year overall global graft-versus-host disease was 43% for haploidentical and 41% for HLA identical (p = 0.8). Overall survival, relapse, and transplant and relapse-related mortality were similar between both groups. Conclusion Our experience showed that haploidentical has similar outcomes to those obtained with HLA idential and can be performed in our country safely.
publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000100040
work_keys_str_mv AT sarmientomauricio haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT ramirezpablo haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT jaraveronica haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT bertinpablo haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT galleguillosmauricio haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT rodriguezisabel haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT lorcacarla haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT pizarroisabel haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT riveraelizabeth haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
AT ocqueteaumauricio haploidenticaltransplantationoutcomesarecomparablewiththoseobtainedwithidenticalhumanleukocyteantigenallogeneictransplantationinchileanpatientswithbenignandmalignanthemopathies
_version_ 1756442055643496448